Trillium Therapeutics Inc. (TSE:TRIL – Get Free Report)’s stock price shot up 0.5% during trading on Monday . The company traded as high as C$23.45 and last traded at C$23.33. 60,423 shares were traded during trading, a decline of 64% from the average session volume of 166,586 shares. The stock had previously closed at C$23.22.
Trillium Therapeutics Trading Up 0.5 %
The firm has a market cap of C$2.45 billion and a PE ratio of -34.06. The company has a current ratio of 12.04, a quick ratio of 11.54 and a debt-to-equity ratio of 0.27. The company has a 50-day moving average of C$23.33.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides.
Featured Stories
- Five stocks we like better than Trillium Therapeutics
- What Is WallStreetBets and What Stocks Are They Targeting?
- Intel: Is Now the Time to Be Brave?
- Stock Market Sectors: What Are They and How Many Are There?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Stock Splits, Do They Really Impact Investors?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
